# Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

> **NCT00266097** · PHASE1 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** oxaliplatin
- **RADIATION:** radiation therapy
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00266097
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2009-03
- **Final completion:** 2011-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266097, "Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00266097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*